The global peptide therapeutics market was valued at $35B in 2021 and is projected to grow at 11% CAGR during the forecast period & reaching over $74B by 2028.
The global peptide therapeutics market was valued at $35B in 2021 and is projected to grow at 11% CAGR during the forecast period & reaching over $74B by 2028. The report analyzes the peptide therapeutics market’s drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the global peptide therapeutics market.
Peptide therapeutics are naturally created disease-treating small chain amino acids known as peptides. They assist humans in hormone creation and are excellent at protecting from infections. Since peptide therapeutics are naturally created by the body, they do not have any side effects and are easily accepted by the body during medical treatments.
Peptide therapeutics are century-old but were only known for their healing abilities. However, with technological advancements and extensive R&D, it was discovered that peptide therapeutics have extreme potential in treating severe diseases with great efficiency.
The global peptide therapeutics market has a substantial presence in the field of acute respiratory disorders, endocrinology, oncology, metabolism disorders, diabetes, dermatology, gastroenterology, and sexual dysfunction. They are also used to treat cardiovascular diseases and bone diseases.
Covid-19 had a positive impact on the global market owing to the increased use of peptide-based drugs in the treatment of the disease. This disrupted the use of peptide therapeutics for the treatment of non-Covid-19 related diseases but the global market has shown signs of steady growth over the forecast period.
Increase in cancer patients and respiratory disorders to propel the global market growth
The growing number of patients suffering from cancer and its after-effects is a leading global market driver. The most prevalent treatment for cancer involves chemotherapy and radiation which leave long-lasting impacts on the patients giving rise to requirements for substitutes like peptide therapeutics. This is expected to move the global peptide therapeutics market forward. Other chronic diseases like diabetes or cardiovascular diseases are also contributing to the global market growth.
Rising demand for drugs that have minimal to no side effects like peptide therapeutics is attributed to becoming the global market driver during the forecast period.
Exhaustive R&D on diseases that might raise global concerns and which can be treated by peptide therapeutics in the future is anticipated to drive the global market.
Unstable nature of peptide therapeutics likely to hamper the market growth
Peptide therapeutics are extremely unstable rendering them difficult to be used. They can aggregate quickly resulting in damage to healthy cells. The volatility of peptide proteins is projected to act as a restraining factor for the global market growth.
In most cases, peptide therapeutics cannot be administered orally. The invasive techniques used for the intake of peptide-based drugs may cause reluctance amongst certain sections of the global population and are anticipated to restrain the global market during the forecast period.
Peptide therapeutics lack deep membrane permeability thus reducing the overall efficiency of the products, which is further anticipated to restrict the global market growth.
Peptide therapeutics tend to oxidize under improper care. The easy oxidization of peptide proteins increases task tediousness and is expected to hamper the global market.
The advent of multi-functional peptide therapeutics to bring growth prospects in the coming period
The global peptide therapeutics market has immense opportunities given the innumerable benefits of peptide-based drugs. The creation of multi-functional peptide therapeutics with an even wider array of use is anticipated to provide excellent growth opportunities in the global market.
Increased innovation in alternate delivery modes of peptide therapeutics is expected to open multiple opportunities for the global market during the forecast period.
Even though the presence of peptide therapeutics in the human body has been for more than a century, their discovery is a recent event. With every passing day more & more peptide therapeutics are added to the global market. As of 2022, there are more than 200 peptide therapeutics in the global market and with ongoing R&D, more are expected to be added soon.
This is anticipated to open multiple growth opportunities in the global market.
The shift towards proteomics, high cost of peptide therapeutics along with quick expiration of patents to challenge the global market growth
The global market is expected to move toward the study of proteins also called proteomics to create substitutes for peptide-based drugs which is anticipated to challenge the global market growth during the forecast period.
The development of peptide therapeutics is an expensive affair and the high cost of production & maintenance is anticipated to create challenging situations in the global market.
The creation of novel drugs requires approval from regulatory bodies and the approval process is extremely stringent which is anticipated to become a challenging factor in the global market.
A considerable number of patents for peptide therapeutics expire quickly which results in heavy losses to drug manufacturers and is anticipated to oppose the global market growth during the forecast period.
The global peptide therapeutics market is segmented by route of administration, type, type of manufacturers, type of molecule, technology, application, and region
Based on the route of administration, the global market is segmented into parenteral, oral, and others. Currently, the global market is led by the parenteral mode, however, the global market is anticipated to be led by the oral mode of administration, during the forecast period.
Based on the type of manufacturers, the global market is segmented as in-house and outsourced. In-house manufacturing shares the highest market share and the same trend is anticipated during the forecast period, because of stringent rules laid down by regulatory bodies.
Based on the type of molecule, the global market is segmented as vasopressin, somatostatin, calcitonin, immunopeptide, natriuretic, and others. Immunopeptide is projected to lead the global market share because of its effective use in the treatment of tumors and cancer.
Based on technology, the global market is segmented into liquid phase, solid phase, and hybrid phase. The largest global market share was held by the liquid phase and is expected to continue with the same trend during the forecast period.
Based on the application, the global market share was shadowed by cancer treatment previously. Since 2020, the global market share was dominated Covid-19 related treatments. However, cancer is anticipated to become the lead contributor during the forecast period.
|Historic Years||2016 - 2020|
|Forecast Years||2021 - 2028|
|Segments Covered||By Product Type, By Application, and By End Use|
|Forecast Units||Value (USD Billion), and Volume (Units)|
|Quantitative Units||Revenue in USD million/billion and CAGR from 2021 to 2028|
|Regions Covered||North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World|
|Countries Covered||U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others|
|Number of Companies Covered||10 companies with scope for including additional 15 companies upon request|
|Report Coverage||Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.|
|Customization Scope||Avail customized purchase options to meet your exact research needs.|
North America to lead the global market during the forthcoming period
The global peptide therapeutics market is anticipated to be led by North America. This region is the hub of key pharmaceutical players, high technology, R&D investment capacity, and world-class cancer treatment facilities, making it a heavily contributing region in the global market.
Europe is expected to show steady growth in the global market because of its advanced healthcare infrastructure and growing awareness related to peptide therapeutics.
Asia-Pacific & the Middle East witnessed a rise in the global market because of Covid-19. Rising cancer, diabetes, and acute respiratory disorders along with increased healthcare investments are anticipated to assist the global market growth.
Africa & Latin America are expected to grow slowly owing to a lack of information on peptide therapeutics along with an absence of necessary healthcare infrastructure, resources, and treatment facilities.
The global peptide therapeutics market is led by key players like Teva Pharmaceutical Industries, AstraZeneca, Sanofi S.A, Amazen Inc., Takeda Pharmaceutical, Ipsen S.A, Merck & Co., Novo Nordisk A/S, GlaxoSmithKline plc, Ever Neuro Pharma, Eli Lilly and Company, CordenPharma International.
The global peptide therapeutics market is segmented as follows:
Peptide therapeutics is a type of treatment in which the peptides are used to activate the functions of the cells against the diseases. The peptide is a signaling molecule which binds to the receptors on the cells to activate the cell to secrete molecules.
According to WHO (World Health Organization), the population aged above 65 years is expected to increase to 2 billion by 2050. Mainly the population above 65 years suffers from various chronic diseases. This increases the demand for peptide therapy due to an increase in the awareness about the novel and effective drugs. Also, the massive investments made by the government and companies for research & development activities across pharmaceutical, biotechnological, and biopharmaceutical industries is likely to propel the growth of the peptide research, which, in turn, will further fuel the peptide therapeutics market trends. The development of advanced technologies and product in peptide therapy and rise in people suffering from metabolic, cardiovascular, respiratory, and other diseases are some of the factors contributing to the growth of the peptide therapeutics market.
The Peptide therapeutics market is segmented on the administration route, type, type of manufacturers, type of molecule, technology, and application. Based on the route of administration, the market is divided into parenteral, oral, and others. On the basis of type, the peptide therapeutics market is further segmented into generic and innovative. Type of manufacturers includes in-house and outsourced segment. Based on the type of molecule, the market for peptide therapeutics is segmented into natriuretic, somatostatin, vasopressin, immunopeptide, calcitonin, and others. On the basis of technology, the market for peptide therapeutics is further segmented into the liquid phase, hybrid phase, and solid phase. The application segment includes cancer, metabolic disease, cardiovascular disease, infectious disease, respiratory disease, and others.
North America is anticipated to lead the market in the upcoming period due to the advancement in the use of peptide therapeutics as a drug to treat cancer and the rising incidences of chronic diseases and cancer. Asia Pacific peptide therapeutics market is expected to show the highest growth, owing to the presence of established API providers and generic industry with the stable economy rate in some countries of Asia Pacific. Also, the increased investment in biotechnological & pharmaceutical industry by government and companies are driving the growth of the peptide therapeutics market.
The main players in the global peptide therapeutics market are Amgen Inc., Pfizer Inc., Eli Lilly and Company, Teva Pharmaceuticals Industries Ltd., Lonza Inc., Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb, Sanofi, AstraZeneca PLC, and Novartis AG. The main companies are focusing on increasing mergers, collaborations, and acquisitions. For instance, Cancer Research UK entered an agreement with Bicycle Therapeutics for funding the clinical trial of Phase Ia and Ib which can be used for the treatment of solid tumors.
The growing number of patients suffering from cancer and its after-effects is a leading global market driver. Cancer isn’t the only disease propelling the global market, but other chronic diseases like diabetes or cardiovascular diseases also contribute to the global market.
Rising demands for drugs that have minimal to no side effects are attributed as the global market drivers during the forecast period.
Exhaustive R&D on diseases that might raise global concerns in the future is also anticipated to drive the global market.
According to Zion Market Research, the global peptide therapeutics market was valued at $35B in 2021 and is projected to grow at 11% CAGR during the forecast period & reaching over $74B by 2028
The global peptide therapeutics market is anticipated to be led by North America. North America is the hub of key pharmaceutical players, high technology, R&D investment capacity, and world-class cancer treatment facilities, making it a heavily contributing region in the global market.
The global peptide therapeutics market is led by key market players like Teva Pharmaceutical Industries, AstraZeneca, Sanofi S.A, Amazen Inc., Takeda Pharmaceutical, Ipsen S.A, Merck & Co., Novo Nordisk A/S, GlaxoSmithKline plc, Ever Neuro Pharma, Eli Lilly and Company, CordenPharma International.